Metastatic behavior of breast cancer subtypes

Journal of Clinical Oncology

Volumn 28, Issue 20, 2010, Pages 3271-3277

  Kennecke, Hagen ^a   Yerushalmi, Rinat ^a   Woods, Ryan ^a   Cheang, Maggie Chon U ^a   Voduc, David ^a   Speers, Caroline H ^a   Nielsen, Torsten O ^a   Gelmon, Karen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER LOCALIZATION; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; BONE TUMOR; BREAST TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; TISSUE MICROARRAY;

AGED; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE ARRAY ANALYSIS;

EID: 77954740501     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.9820     Document Type: Article

References (51)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Alanko A, Heinonen E, Scheinin T, et al: Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer 56:1696-1700, 1985 (Pubitemid 15228524)
3. Chia S, Norris B, Speers C, et al: Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26:5697-5704, 2008
4. Norton L, Massague J: Is cancer a disease of self-seeding? Nat Med 12:875-878, 2006
5. Paget S: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8:98-101, 1989
6. Chiang AC, Massague J: Molecular basis of metastasis. N Engl J Med 359:2814-2823, 2008
7. Minn AJ, Gupta GP, Padua D, et al: Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A 104:6740-6745, 2007 (Pubitemid 47175571)
8. Kang Y, Siegel PM, Shu W, et al: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-549, 2003 (Pubitemid 36808649)
9. Gupta GP, Nguyen DX, Chiang AC, et al: Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446:765-770, 2007 (Pubitemid 46582040)
10. Minn AJ, Gupta GP, Siegel PM, et al: Genes that mediate breast cancer metastasis to lung. Nature 436:518-524, 2005 (Pubitemid 41112921)
11. Smid M, Wang Y, Klijn JG, et al: Genes associated with breast cancer metastatic to bone. J Clin Oncol 24:2261-2267, 2006 (Pubitemid 46630655)
12. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 360:790-800, 2009
13. Clayton AJ, Danson S, Jolly S, et al: Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639-643, 2004 (Pubitemid 39141617)
14. Dawood S, Broglio K, Esteva FJ, et al: Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19: 1242-1248, 2008 (Pubitemid 351911952)
15. Gaedcke J, Traub F, Milde S, et al: Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol 20:864-870, 2007 (Pubitemid 47077270)
16. Hess KR, Pusztai L, Buzdar AU, et al: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78:105-118, 2003 (Pubitemid 36223023)
17. Hicks DG, Short SM, Prescott NL, et al: Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 30:1097-1104, 2006 (Pubitemid 44299342)
18. Lin NU, Bellon JR, Winer EP: CNS metastases in breast cancer. J Clin Oncol 22:3608-3617, 2004 (Pubitemid 41103668)
19. Maki DD, Grossman RI: Patterns of disease spread in metastatic breast carcinoma: Influence of estrogen and progesterone receptor status. Am J Neuroradiol 21:1064-1066, 2000 (Pubitemid 30390543)
20. Slimane K, Andre F, Delaloge S, et al: Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 15:1640-1644, 2004 (Pubitemid 39562604)
21. Tham YL, Sexton K, Kramer R, et al: Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 107:696-704, 2006 (Pubitemid 44232661)
22. Weil RJ, Palmieri DC, Bronder JL, et al: Breast cancer metastasis to the central nervous system. Am J Pathol 167:913-920, 2005 (Pubitemid 41416243)
23. Smid M, Wang Y, Zhang Y, et al: Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108-3114, 2008
24. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
25. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
26. Cheang MC, Voduc D, Bajdik C, et al: Basallike breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368-1376, 2008 (Pubitemid 351413917)
27. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374, 2004 (Pubitemid 39100473)
28. Cheang MC, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750, 2009
29. Voduc D, Cheang M, Nielsen T: GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev 17:365-373, 2008 (Pubitemid 351272788)
30. Cheang MC, Treaba DO, Speers CH, et al: Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24:5637-5644, 2006 (Pubitemid 46631303)
31. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
32. Pritchard KI, Shepherd LE, O'Malley FP, et al: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111, 2006 (Pubitemid 43736610)
33. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
34. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
35. Burstein HJ, Lieberman G, Slamon DJ, et al: Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 16:1772-1777, 2005 (Pubitemid 41631239)
36. Kennecke H, McArthur H, Olivotto IA, et al: Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Cancer 112:1437-1444, 2008 (Pubitemid 351441156)
37. Saphner T, Tormey DC, Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746, 1996 (Pubitemid 26329660)
38. Kennecke HF, Olivotto IA, Speers C, et al: Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 18:45-51, 2007 (Pubitemid 46152498)
39. Miller KD, Weathers T, Haney LG, et al: Occult central nervous system involvement in patients with metastatic breast cancer: Prevalence, predictive factors and impact on overall survival. Ann Oncol 14:1072-1077, 2003 (Pubitemid 36950171)
40. Dawood S, Broglio K, Esteva FJ, et al: Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 20:621-627, 2009
41. Gabos Z, Sinha R, Hanson J, et al: Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24:5658-5663, 2006 (Pubitemid 46631306)
42. Saip P, Cicin I, Eralp Y, et al: Factors affecting the prognosis of breast cancer patients with brain metastases. Breast 17:451-458, 2008
43. Bendell JC, Domchek SM, Burstein HJ, et al: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972-2977, 2003 (Pubitemid 36676250)
44. Altaha R, Crowell E, Ducatman B, et al: Risk of brain metastases in HER2/neu-positive breast cancer. J Clin Oncol 22:47, 2004 (suppl 14; asbstr 682)
45. Recommended breast cancer surveillance guidelines: American Society of Clinical Oncology. J Clin Oncol 15:2149-2156, 1997
46. Smith TJ, Davidson NE, Schapira DV, et al: American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 17:1080-1082, 1999
47. Khatcheressian JL, Wolff AC, Smith TJ, et al: American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24:5091-5097, 2006
48. Pantel K, Alix-Panabieres C, Riethdorf S: Cancer micrometastases. Nat Rev Clin Oncol 6:339-351, 2009
49. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
50. McClung MR, Lewiecki EM, Cohen SB, et al: Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831, 2006 (Pubitemid 43290920)
51. Hugh J, Hanson J, Cheang MCU, et al: Breast cancer subtypes and response to docetaxel in node positive breast cancer; use of an immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol 27:1168-1176, 2009